PLVAP and Autoimmunity: Altogether, our data suggests that PV1 blockade acts by suppressing effector T cell responses in general, but mainly in antigen-specific TH1 lymphocytes rendering these cells unable to exert their effector functions upon antigen re-encounter in the target organ, similar to what was found after FR104 treatment in non-human primate models of skin inflammation [36] and autoimmunity [38].